Biocell Of Israel Vetoes Liquidation, Direct Investor Share Of Protalix
This article was originally published in PharmAsia News
Executive Summary
The board of Israel's Biocell voted against selling the company's 17% stake in Protalix Biotherapeutics, the only thing Biocell owns